Table 4

Secondary outcomes: progression/regression of mRSS and decline/increase of FVC

Estimated treatment effect of TCZ with OR (95% CI)0.7 (0.1 to 4.8)1.1 (0.4 to 2.7)0.8 (0.3 to 2.2)1.5 (0.6 to 3.8)
P values0.740.860.630.41
  • These results represent our main analysis with a nearest neighbour matching algorithm and selection of most recent observation in control patients with multiple possible baseline observations.

  • CI, confidence interval; FVC, forced vital capacity; mRSS, modified Rodnan skin score; OR, odds ratio; TCZ, tocilizumab.